Diabetes News and Research

Latest Diabetes News and Research

Kidney disease genes discovered

Chronic kidney disease affects one in 10 adults and can severely damage a patient’s quality of life over years. This disease is linked to advanced age with one in five men and one in four women aged between 65 and 74 developing some degree of kidney damage.

12 Apr 2010

Johns Hopkins Hospital launches Meatless Monday campaign to encourage healthier

The Johns Hopkins Hospital will launch a campaign on Monday, April 12 to encourage healthier eating among patients, visitors and staff — Meatless Monday.

12 Apr 2010

Resverlogix highlights features of RVX-208 drug at ATVB conference

Resverlogix Corp. announced today that key scientific data was communicated in an oral presentation highlighting the novel features of RVX-208, the Company's lead drug, during the Atherosclerosis, Thrombosis, Vascular Biology conference being held in San Francisco, California.

12 Apr 2010

Study pioneers phenotyping of human metabolome

The old excuse, "I am only overweight because of my genes," is suddenly gaining credibility as researchers uncover ever more evidence that the way our bodies digest and process nutrients in the food we eat is different for every person. The budding discipline of metabolomics strives to investigate these differences in a scientific manner.

12 Apr 2010

List of MCEG's Annual Top Ten issues

Likely to be the first professional healthcare group to meet immediately after healthcare reform legislation passed, the Managed Care Executive Group held its annual forum in Ft. Lauderdale, Florida last week.

9 Apr 2010

FDA grants 510(K) clearance to market Vitala Continence Control Device

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today that the U.S. Food and Drug Administration has granted 510(K) clearance to market Vitala, an exceptionally innovative, non-intrusive ostomy continence control device, for people with an end colostomy.

9 Apr 2010

Research roundup: The effects of health IT, doctor-owned treatment centers, long-term care issues

Physician-Ownership Of Ambulatory Surgery Centers Linked To Higher Volume Of Surgeries - The authors analyzed data from Florida, using the Healthcare Cost and Utilization Project's State Ambulatory Surgery Databases, revealing "a significant association between physician-ownership of surgicenters and greater use" of certain outpatient procedures.

9 Apr 2010

IMAGE project to be launched for prevention of type 2 diabetes

Researchers and clinicians from across the UK have been part of a pan-European team that has developed the first Europe wide strategy for the prevention of type 2 diabetes. The project received substantial funding of -1.2 million from the European Union.

9 Apr 2010

Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that researchers from the Mayo Clinic will be presenting data on the use of XOMA's high-affinity antibody to interleukin-1 beta (IL-1 beta), XOMA 052, in myeloma at the 101st Annual Meeting of the American Association of Cancer Research (AACR).

9 Apr 2010

BeaconEquity.com announces investment report featuring Avanir Pharmaceuticals

BeaconEquity.com announces an investment report featuring Avanir Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

Independent management of diabetes a huge issue for teens

It is hard enough being a teenager − or the parent of a teenager − without also having to deal with type 1 diabetes. Keeping good control can be a problem when the responsibility for administering insulin and checking blood glucose levels passes from parent to child.

9 Apr 2010

Researchers show iRGD peptide increases treatment efficacy against cancer

Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.

9 Apr 2010

"Nanovaccine" reverses diabetes

A new study, published online April 8 by Cell Press in the journal Immunity, describes a unique therapeutic "nanovaccine" that successfully reverses diabetes in a mouse model of the disease. In addition to providing new insight into diabetes, the research also reveals an aspect of the pathogenesis of the autoimmune response that may provide a therapeutic strategy for multiple autoimmune disorders.

9 Apr 2010

PESA CNIC-Santander trial initiative to increase knowledge about cardiovascular diseases

Felipe P-triz, Secretary of State for Research and Emilio Bot-n, President of the Grupo Santander, signed today a milestone agreement giving birth to the PESA (Progression of Early Subclinical Atherosclerosis) CNIC-Santander trial. The project's main goal is to increase the knowledge about cardiovascular diseases.

9 Apr 2010

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ChemoCentryx, Inc., today announced that it has identified a novel drug candidate targeting the chemoattractant receptor known as ChemR23. This investigational new drug, designated CCX832, is an orally-administered small molecule antagonist of ChemR23, an important player in inflammatory disease.

9 Apr 2010

Generex Biotechnology, Seaside 88 close first tranche of 2 million shares for gross proceeds of $945,180

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has entered into a common stock purchase agreement with Seaside 88, LP, a private investment limited partnership. Seaside has committed to purchase up to 49,455,130 shares of Generex common stock.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

Russia's first implant of SynCardia temporary CardioWest Total Artificial Heart performed on 60-year-old female

On March 23, the Bakoulev Scientific Center for Cardiovascular Surgery (BSCCS) in Moscow performed Russia's first implant of the SynCardia temporary CardioWest™ Total Artificial Heart. The patient, a 60-year-old female suffering from biventricular heart failure, is the world's 850th recipient of the Total Artificial Heart.

9 Apr 2010

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.

9 Apr 2010

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.

9 Apr 2010